EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function

Atsushi Takayama iD, Toshiki Fukasawa, Masato Takeuchi, Koji Kawakami

Modern Rheumatology · 2025

DOI: 10.1093/mr/roae115 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Atsushi Takayama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan. Hauptthemen laut MEDLINE: Febuxostat, Allopurinol, Hyperuricemia, Gout Suppressants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Early initiation of xanthine oxidase inhibitors may benefit patients with preserved kidney function. However, a direct comparison between the impact of allopurinol and that of febuxostat on long-term kidney function among this population is lacking.

Methods

We conducted a retrospective cohort study with a new-user, active-comparator design among patients with estimated glomerular filtration rate (eGFR) within the reference range and no proteinuria. The primary outcome was a composite incidence of significant eGFR decline (≥40% decline from baseline) and all-cause death at 5 years. Adjusted hazard ratios were estimated using Cox’s proportional hazard models with inverse probability of treatment and censoring weighting.

Results

We analysed 1142 patients (287 with allopurinol and 855 with febuxostat). The adjusted hazard ratios (95% confidence intervals) for allopurinol initiators compared to febuxostat initiators for the composite outcome at 5 years were 0.84 (0.74–0.95). The cause-specific adjusted hazard ratios for allopurinol initiators relative to febuxostat initiators were 0.82 (0.70–0.94) for significant eGFR decline >5 years and 1.08 (0.91–1.24) for all-cause death >5 years.

Conclusions

Allopurinol initiators preserved kidney function better than febuxostat >5 years. Clinicians should exercise caution not only when prescribing but also when selecting xanthine oxidase inhibitors, even for patients with preserved kidney function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FebuxostatAllopurinolHyperuricemiaGout SuppressantsKidneyHumansMaleFemaleRetrospective StudiesMiddle AgedGlomerular Filtration RateAgedTreatment OutcomeXanthine Oxidase

Stichwörter der Autor:innen

Allopurinolfebuxostatglomerular filtration rategouthyperuricaemia

Substanzen

FebuxostatAllopurinolGout SuppressantsXanthine Oxidase

Autor:innen und Institutionen

  • Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan.
  • Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.

ORCID-Profile: Atsushi Takayama

Zitieren

APA

Takayama, A., Fukasawa, T., Takeuchi, M., & Kawakami, K. (2025). Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function. Modern Rheumatology. https://doi.org/10.1093/mr/roae115

Vancouver

Takayama A, Fukasawa T, Takeuchi M, Kawakami K. Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function. Modern Rheumatology. 2025. doi:10.1093/mr/roae115

BibTeX
@article{Takayama2025,
  author = {Takayama, Atsushi and Fukasawa, Toshiki and Takeuchi, Masato and Kawakami, Koji},
  title = {Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricaemic patients with preserved kidney function},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roae115}
}
Kostenlos starten →